Home
|
Inbox
|
Search
|
View Abstract
Mouse Model of Immune Response Modulation in Malignant Pleural Effusion
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A2691 - Mouse Model of Immune Response Modulation in Malignant Pleural Effusion
Author Block: C. Merrick1, T. P. Sherrill1, I. Psallidas2, T. S. Blackwell1, F. Maldonado1; 1Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, United States, 2Oxford Centre for Respiratory Medicine, Oxford, United Kingdom.
Rationale: Malignant pleural effusion (MPE) is a significant cause of morbidity and marker of high mortality among patients with metastatic malignancy. Therapeutic options include serial thoracenteses, chemical pleurodesis, indwelling pleural catheters (IPCs) or a combination thereof. Intrapleural therapy options are currently limited. In a time of growing utilization of immune therapy we seek to develop a mouse model of MPE which utilizes intrapleural injection of microbial antigens. We hypothesize that microbial antigen injection will elicit host immune response and in turn enhance tumor killing and host survival.
Methods: Using C57B/6 mice, we create a MPE by intrapleural injection of Lewis lung carcinoma (LLC) cells. Following effusion development, microbial antigen (either Lipoteichoic acid-T or Beta-D-glucan) is injected into the pleural space. Using in vivo imaging systems, pleural inflammation and tumor burden are monitored at set intervals for remaining mouse lifespan. Following mouse sacrifice, pleural fluid inflammatory profile, effusion volume, and tumor burden are all evaluated.
Results: Using this model, our preliminary data are suggestive of survival benefit among mice receiving intrapleural therapy. However, there is no notable difference in effusion volume, degree of inflammation, or tumor burden at this time between control and test groups.
Conclusions: Further work remains to be done in our mouse model of MPE as we seek to enhance tumor killing through local immune modulation. Ongoing efforts are targeted toward drug dose escalation and administration frequency to determine optimal host response.
Author Block: C. Merrick1, T. P. Sherrill1, I. Psallidas2, T. S. Blackwell1, F. Maldonado1; 1Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, United States, 2Oxford Centre for Respiratory Medicine, Oxford, United Kingdom.
Rationale: Malignant pleural effusion (MPE) is a significant cause of morbidity and marker of high mortality among patients with metastatic malignancy. Therapeutic options include serial thoracenteses, chemical pleurodesis, indwelling pleural catheters (IPCs) or a combination thereof. Intrapleural therapy options are currently limited. In a time of growing utilization of immune therapy we seek to develop a mouse model of MPE which utilizes intrapleural injection of microbial antigens. We hypothesize that microbial antigen injection will elicit host immune response and in turn enhance tumor killing and host survival.
Methods: Using C57B/6 mice, we create a MPE by intrapleural injection of Lewis lung carcinoma (LLC) cells. Following effusion development, microbial antigen (either Lipoteichoic acid-T or Beta-D-glucan) is injected into the pleural space. Using in vivo imaging systems, pleural inflammation and tumor burden are monitored at set intervals for remaining mouse lifespan. Following mouse sacrifice, pleural fluid inflammatory profile, effusion volume, and tumor burden are all evaluated.
Results: Using this model, our preliminary data are suggestive of survival benefit among mice receiving intrapleural therapy. However, there is no notable difference in effusion volume, degree of inflammation, or tumor burden at this time between control and test groups.
Conclusions: Further work remains to be done in our mouse model of MPE as we seek to enhance tumor killing through local immune modulation. Ongoing efforts are targeted toward drug dose escalation and administration frequency to determine optimal host response.
|
Home
|
Inbox
|
Search
|